Literature DB >> 9699904

Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.

C Marcoux1, M Tremblay, A Fredenrich, H Jacques, L Krimbou, K Nakajima, J Davignon, J S Cohn.   

Abstract

Remnant-like particle (RLP) lipid and apolipoprotein (apo) levels were determined in the plasma of normolipidemic and hyperlipidemic subjects, in order to investigate the relationship between RLP levels and the concentration of other plasma lipoprotein parameters. Plasma RLP fractions were isolated with the use of an immunoaffinity gel (RLP-Cholesterol Jimro II, Japan Immunoresearch Lab.), containing specific anti-apoB-100 and anti-apoA-I antibodies. Four groups of human subjects were selected, who had either matching or significantly different levels of plasma triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C): (1) normolipidemic control (NC) subjects (n = 10), (2) patients with elevated levels of LDL-C (type IIa, LDL-C (mean +/- S.E.), 4.65 +/- 0.09 mmol/l, n = 10), (3) hypertriglyceridemic (HTG) patients with elevated LDL-C (type IIb, TG: 3.86 +/- 0.36; LDL-C: 4.67 +/- 0.21 mmol/l, n = 10), and (4) HTG patients with normal LDL-C (type IV, TG: 3.71 +/- 0.39 mmol/l, n = 10). NC subjects (RLP-C: 0.22 +/- 0.01; RLP-TG: 0.24 +/- 0.03 mmol/l) had RLP apoB, apoC-III and apoE levels of 3.2 +/- 0.3, 1.8 +/- 0.3, and 1.4 +/- 0.1 mg/dl, representing 3.2 +/- 0.4, 14.5 +/- 1.4 and 32.1 +/- 2.1% of total plasma levels, respectively. RLP lipid and apolipoprotein concentrations were significantly higher in HTG groups (type IIb and IV) compared to NTG groups (NC and type IIa) (e.g. RLP-C: 0.50 +/- 0.07 and 0.58 +/- 0.11 vs. 0.22 +/- 0.01 and 0.21 +/- 0.01 mmol/l, respectively (P < 0.01); RLP apoB: 8.4 +/- 1.6 and 8.2 +/- 0.9 vs. 3.2 +/- 0.3 and 3.4 +/- 0.2 mg/dl, respectively (P < 0.01)). No significant difference in RLP levels was observed between groups having different LDL levels, and thus no correlation existed between RLP-C and LDL-C levels (r = 0.24, n.s.). RLP-C and RLP apoB levels were, however, correlated with VLDL-C and VLDL apoB (r = 0.86, P < 0.001 and r = 0.70, P < 0.001, respectively). These results demonstrate that elevated levels of both RLP lipids and apolipoproteins are characteristic of patients with increased levels of plasma triglyceride, and not patients with increased levels of LDL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699904     DOI: 10.1016/s0021-9150(98)00042-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

Review 1.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

Review 2.  Remnant lipoproteins and atherosclerosis.

Authors:  ThB Twickler; G M Dallinga-Thie; M J Chapman; J S Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

3.  A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression.

Authors:  Amar Bahadur Singh; Chin Fung Kelvin Kan; Vikram Shende; Bin Dong; Jingwen Liu
Journal:  J Lipid Res       Date:  2014-05-02       Impact factor: 5.922

Review 4.  Biochemical aspects of overtraining in endurance sports : the metabolism alteration process syndrome.

Authors:  Cyril Petibois; Georges Cazorla; Jacques-Rémi Poortmans; Gérard Déléris
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

5.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.

Authors:  Kimber L Stanhope; Jean Marc Schwarz; Nancy L Keim; Steven C Griffen; Andrew A Bremer; James L Graham; Bonnie Hatcher; Chad L Cox; Artem Dyachenko; Wei Zhang; John P McGahan; Anthony Seibert; Ronald M Krauss; Sally Chiu; Ernst J Schaefer; Masumi Ai; Seiko Otokozawa; Katsuyuki Nakajima; Takamitsu Nakano; Carine Beysen; Marc K Hellerstein; Lars Berglund; Peter J Havel
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.